Evidence map›Paper›PMID 27126993›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016

Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors.

Ya'an Kang, David Roife, Yeonju Lee, Hailong Lv, Rei Suzuki, Jianhua Ling, Mayrim V Rios Perez, Xinqun Li, BingBing Dai, Michael Pratt and 9 more

Open access · greenAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. TFEB-driven autophagy potentiates TGF-β induced migration in pancreatic cancer cells.Journal of experimental & clinical cancer research : CR · 2019
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 3 countries.

Ya'an KangDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
David RoifeDepartment of General Surgery, The University of Texas Health Science Center at Houston, Houston, Texas.
Yeonju LeeDivision of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hailong LvDepartment of Hepatobiliary Surgery, The First Affiliated Hospital, School of Medicine, Shihezi University, Xinjiang, China.
Rei SuzukiDepartment of Gastroenterology and Rheumatology, The Fukushima Medical University School of Medicine, Fukushima, Japan.
Jianhua LingDepartment of Molecular and Cellular Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mayrim V Rios PerezDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Xinqun LiDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
BingBing DaiDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael PrattDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mark J TrutyDepartment of Surgery, Mayo Clinic, Rochester, Minnesota.
Deyali ChatterjeeDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas.
Huamin WangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ryan M ThomasDepartment of General Surgery, The University of Florida College of Medicine, Gainesville, Florida.
Yu WangNeurodiagnostics Laboratory, The University of Texas Medical Branch, Galveston, Texas.
Eugene J KoayDivision of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Paul J ChiaoDepartment of Molecular and Cellular Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Matthew H KatzDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jason B FlemingDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. jbflemin@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USFirst Affiliated Hospital of Shihezi University Medical College · CNFukushima Medical University · JPMayo Clinic · USThe University of Texas Health Science Center at Houston · USThe University of Texas Medical Branch at Galveston · USUniversity of Florida · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
TRAINING OF ACADEMIC SURGICAL ONCOLOGISTST32CA009599 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Ashley M Holder, Jennifer A. Wargo · 1988 to 2026
$13.2M
VEGF Promotes Pancreatic Tumor Cell Arrest in the LiverR21CA106669 · NCI · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI FLEMING, JASON B · 2004 to 2005
$211k
NCI NIH HHS P30 CA016672NCI NIH HHS R21 CA106669NCI NIH HHS T32 CA009599
6 · The paper itself

Abstract

purposePancreatic ductal adenocarcinoma (PDAC) is lethal cancer whose primary tumor is characterized by dense composition of cancer cells, stromal cells, and extracellular matrix (ECM) composed largely of collagen. Within the PDAC tumor microenvironment, activated pancreatic stellate cells (PSC) are the dominant stromal cell type and responsible for collagen deposition. Lumican is a secreted proteoglycan that regulates collagen fibril assembly. We have previously identified that the presence of lumican in the ECM surrounding PDAC cells is associated with improved patient outcome after multimodal therapy and surgical removal of localized PDAC. EXPERIMENTAL

designLumican expression in PDAC from 27 patients was determined by IHC and quantitatively analyzed for colocalization with PSCs. In vitro studies examined the molecular mechanisms of lumican transcription and secretion from PSCs (HPSCs and HPaSteC), and cell adhesion and migration assays examined the effect of lumican on PSCs in a collagen-rich environment.

resultsHere we identify PSCs as a significant source of extracellular lumican production through quantitative IHC analysis. We demonstrate that the cytokine, TGF-β, negatively regulates lumican gene transcription within HPSCs through its canonical signaling pathway and binding of SMAD4 to novel SBEs identified within the promoter region. In addition, we found that the ability of HPSCs to produce and secrete extracellular lumican significantly enhances HPSCs adhesion and mobility on collagen.

conclusionsOur results demonstrate that activated pancreatic stellate cells within PDAC secrete lumican under the negative control of TGF-β; once secreted, the extracellular lumican enhances stellate cell adhesion and mobility in a collagen-rich environment. Clin Cancer Res; 22(19); 4934-46. ©2016 AACR.

Indexed as

AnimalsCarcinoma, Pancreatic DuctalGene Expression Regulation, NeoplasticHeterograftsHumansLumicanMicePancreatic NeoplasmsPancreatic Stellate CellsTransforming Growth Factor betaTumor MicroenvironmentLumicanLUM protein, humanTransforming Growth Factor beta

Identifiers

PMID27126993
PMCPMC5127652
OpenAlexW2344736690

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.